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Abstract
Objectives—HIV rapid antibody tests are widely used in Africa, but dual testing sometimes 
produces discordant results. It is not clear if discordant rapid HIV tests should always heighten 
suspicion by frontline health workers that early HIV infection is present. Some studies have 
reported that discordant rapid tests have value for identifying early HIV infection in high HIV 
prevalence populations. It is not known if rapid test performance influenced this conclusion, or if 
this observation will hold true for low HIV prevalence populations. We therefore explored the 
occurrence of discordant rapid HIV tests in a low-resource community.
Methods—A cross-sectional sample of HIV status-unaware adults with recent exposure to unsafe 
sex was assessed using a validated risk-based tool (University of North Carolina (UNC)-Malawi 
Risk Screening Score) for acute HIV infection. Participants received rapid testing with 
Determine™ HIV 1/2 and Uni-Gold™ HIV assays, plus plasma HIV-1 antigen testing with the 
COBAS® Ampliprep/COBAS® Taqman® HIV-1 assay, followed by western blot in those with 
detected HIV-1 antigen.
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Results—Of 408 participants, 1.0% were confirmed to have established HIV infection. The 
discordance between rapid tests at initial screening was 2.45 and 2.94% when the two assays were 
used sequentially and simultaneously, respectively. Discordant rapid tests were strongly associated 
with risk scores > 2 [odds ratio (OR) 10.88; 95% confidence interval (CI) 2.35–50.43], and with 
detected HIV-1 RNA (OR 26.06; 95% CI 3.91–173.60).
Conclusions—When the sample occurrence of discordance between the first and second tests is 
below 5%, discordant rapid tests in an adult with sexual risk behaviour should trigger strong 
suspicion of early HIV infection in low HIV prevalence populations.
Keywords
acute HIV infection; Africa; discordant rapid tests; early HIV infection; HIV; HIV antibody test; 
rapid HIV test
Introduction
Over the last decade, HIV testing has been scaled up across sub-Saharan Africa such that 
testing is sometimes performed in nonlaboratory settings by lay persons using point-of-care 
tests. Low-budget screening programmes predominantly use rapid diagnostic tests (RDTs) 
that are based on immunochromatographic detection of HIV antibodies. Detection of acute 
HIV infection (AHI) is a challenge in sub-Saharan Africa because recommended antigen-
based HIV tests are not readily available [1].
Serial testing for HIV infection utilizes two different antibody tests sequentially (if the initial 
test is reactive), while parallel testing employs two different antibody tests simultaneously. 
Both testing algorithms sometimes yield discordant results between the first and second 
RDTs, a “reactive versus nonreactive” outcome that requires further testing [2].
Some reports have linked discordant rapid antibody results with AHI. In Malawi, Fiscus and 
colleagues reported that 33% of AHI cases had discordant rapid tests compared with 2% of 
HIV-negative participants [3]. Several studies have reported on the high rate of false positive 
results produced by rapid HIV testing [4–6]. It is not clear if Fiscus et al. took false positive 
results into consideration in arriving at the conclusion of an association between rapid test 
discordance and AHI. In addition, their study was clinic-based and involved patient 
populations with a high HIV prevalence. It is not known whether the said observation will 
hold true for populations with a low HIV prevalence.
We sought to determine the RDT discordance rate at first screening, and the association 
between discordant rapid tests and diagnostic markers of AHI during HIV screening in a 
relevant community with a low HIV prevalence.
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Methods
Study location
A cross-sectional study was conducted from October to December 2015 in Sabo, a multi-
ethnic urban-slum community in Ibadan, Oyo State, Nigeria. Oyo State recorded an HIV 
prevalence of 5.6% in Nigeria’s 2013 HIV/AIDS and Reproductive Health Survey [7].
Recruitment
We conducted 4 weeks of a community awareness drive, and then set up a free HIV 
counselling and testing station within the host community. Consenting adults (age ≥ 18 
years) were recruited if their HIV status was unknown and they self-reported unsafe sex 
within the preceding 2 months. Unsafe sex was defined as unprotected coitus with casual or 
multiple partners with unknown HIV status or confirmed HIV infection. Persons with prior 
HIV post-exposure prophylaxis or antiretroviral treatment were excluded.
Study procedures
At enrolment, each participant received a unique study identifier, and then completed an 
interviewer-administered study questionnaire, which included the UNC-Malawi Risk 
Screening Score (UMRSS) assessment (a validated risk score algorithm in which six 
predictor scores are summed to calculate each participant’s AHI risk score within a possible 
range of 0–11 points). Powers et al.[8] reported that a risk score of ≥ 2 was 95.2% sensitive 
and 60.5% specific for detecting AHI. HIV rapid antibody testing was performed on finger-
prick blood samples on site. All participants received HIV pre-test and post-test counselling. 
Each sample was tested with the Determine™ HIV 1/2 assay (Abbott Laboratories, Japan 
Co., Ltd, Tokyo, Japan) and the Uni-Gold™ HIV assay (Trinity Biotech, Bray, Ireland) 
according to the parallel testing algorithm. Test outcomes for the Determine assay-based 
serial testing algorithm were deduced during data (post hoc) analysis. We considered a test 
result as seropositive if both RDTs were reactive (dual-positive), as seronegative if both 
RDTs were nonreactive (dual negative), and as discordant if one RDT was reactive and the 
other nonreactive. The outcome variables were RDT discordance between Determine and 
Uni-Gold assays at first screening; UNC-Malawi Risk Scores; and plasma HIV-1 RNA 
levels.
Each participant also had 7 mL of blood collected in an ethylenediaminetetraacetic acid 
(EDTA) tube. Plasma was separated within 4 h of blood draw after centrifugation at 1200 g 
for 20 min at the University College Hospital, Ibadan (UCH), and transported to the 
Virology Laboratory, Nigerian Institute of Medical Research, Lagos (NIMR) for HIV-1 
RNA testing using the COBAS® Ampliprep/COBAS® Taqman® HIV-1 Test, version 2.0 
(Roche Moelcular Systems, Branchburg, NJ, USA). This assay reports the HIV target as 
“detected” or “not detected”, and has an HIV-1 RNA quantification range of 20–10 000 000 
HIV-1 RNA copies/mL when the HIV target is detected. A “not detected” result indicates 
that the assay was unable to detect HIV-1 RNA in the plasma specimen tested. Plasma 
samples with detected HIV-1 RNA were further subjected to western blot (WB) to decide 
between two possible diagnostic outcomes: acute or established HIV infection. We defined 
AHI as a composite outcome of (1) dual-negative or discordant RDTs at first screening, (2) 
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detected plasma HIV-1 RNA > 20 copies/mL, and (3) negative WB. Established HIV 
infection was defined as a triple combination of (1) dual-positive or discordant RDTs at first 
screening, (2) detected plasma HIV-1 RNA > 20 copies/mL, and (3) positive WB. 
Participants with HIV infection were referred to the HIV clinic, UCH for clinical care.
Ethical approval
Approval was obtained from the Ethical Review Committee, Oyo State Ministry of Health; 
University of Ibadan/UCH Ethical Committee; and Northwestern University Institutional 
Review Board. Each participant provided written informed consent.
Statistical methods
Data were collected using a structured form, and entered into REDCap (Research Electronic 
Data Capture). Data analysis was performed with STATA 11.0 (StataCorp, College Station, 
TX, USA). The mean UMRSSs for participants with and without RDT discordance were 
compared using a t-test. Odds ratios (ORs) were used to test the associations between 
discordant RDT and UMRSS summated scores, and between discordant RDT and detected 
plasma HIV-1 RNA. The level of statistical significance was set at P ≤ 0.05.
Results
A total of 408 adults with a mean age of 37.7 ± SD14.2 years participated in the study, with 
52.9% being male. The majority of participants were married (59.8%) and employed 
(82.4%), and 48.3% had 10 years or more of primary and secondary education.
At first screening, 408 paired tests were performed using Determine (408 tests) and Uni-
Gold (408 tests) simultaneously. This yielded 394 nonreactive (dual-negative) pairs, 12 
discordant pairs, and two reactive (dual-positive) pairs of results (see Table 1). The 
discordance rate between Determine and Uni-Gold tests was 2.94% when the two RDTs 
were used simultaneously. Post hoc analysis for a serial testing algorithm yielded 396 
nonreactive and 12 reactive Determine (unpaired) results. Sequential application of RDT 2 
(after each reactive Determine test) yielded 10 nonreactive and two reactive Uni-Gold 
results. The overall serial testing outcome was 10 discordant pairs and two reactive (dual-
positive) pairs of results. The discordance rate between Determine and Uni-Gold was 2.45% 
when the two RDTs were used sequentially. There was no statistically significant difference 
(χ2 = 0.18; P = 0.66) between the test discordance rates obtained when the RDTs were used 
simultaneously and sequentially.
For 408 participants, the UMRSSs obtained ranged between 1 and 8 points, with a mean 
UMRSS of 2.56 (SD ± 1.03). For 12 participants with discordant RDT results, the mean 
UMRSS was 5.58 (SD ± 1.98). There was a statistically significant difference (t = 9.67; P = 
0.0001) between these two means. The majority of participants (66.2%) had UMRSS ≤ 2. 
Discordant rapid tests were strongly associated with UMRSS > 2 [OR 10.88; 95% 
confidence interval (CI) 2.35–50.43]. All 408 plasma samples underwent HIV-1 RNA 
analysis. HIV-1 RNA was not detected in 394 (96.6%) samples with nonreactive (dual-
negative) RDTs at first screening (see Table 2). Three (0.7%) samples with nonreactive 
(dual-negative) RDTs at initial testing had HIV-1 RNA detected (< 20 copies/mL), and were 
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WB negative. Of 12 samples with discordant RDTs at initial testing, two (16.7%) samples 
had HIV-1 RNA detected (5681 and 73 779 copies/mL, respectively). Both samples were 
confirmed HIV positive by WB. Discordant rapid tests were strongly associated with 
detected plasma HIV-1 RNA (OR 26.06; 95% CI 3.91–173.60). Overall, four (out of 408) 
participants were confirmed to be HIV-infected, a HIV seroprevalence rate of 1.0%. No AHI 
case was identified.
Discussion
A discordant rapid HIV test result arises when one of the tests is falsely negative or falsely 
positive. The occurrence of discordant rapid tests (Determine/Uni-Gold) in this study was 
approximately 3% for either parallel or serial algorithms. This operating characteristic is 
within the World Health Organization (WHO) recommendation that the discordance of 
results between first and second tests should not exceed 5% [2]. A false negative test may 
occur as a result of low stability of antibody expression soon after establishment of HIV 
infection [9]. In our study, more than half of all the discordant rapid tests involved reactive 
(false positive) Determine and nonreactive (true negative) Uni-Gold results. Several studies 
have reported a high rate of false positive results produced by rapid HIV testing [4–6]. An 
interim analysis of data from Ethiopia reported a 7% false positive rate using the national 
algorithm which relied on two concordant (out of three) RDT results for HIV diagnosis [10]. 
Endemic infections [11], heightened CD5 expression and early B-lymphocyte response 
polyclonal cross-reactivity [5] may contribute to HIV false positivity in certain settings. 
Researchers conducting clinical trials using RDTs in Uganda have noted that the high false 
positive rates observed may be attributable to misinterpretation of weakly positive bands 
[12]. Other reports have corroborated this observation, particularly for the Determine HIV 
1/2 assay [13]. The intensity of positive bands on Determine HIV 1/2 was not coded in our 
study, and the possibility of observer error cannot be ruled out.
In the clinic-based study by Fiscus et al.,[3] of 1450 adults offered voluntary HIV 
counselling and testing in Malawi using two RDTs, approximately 40% turned out to have 
established HIV infection, a notably high seroprevalence rate. Discordant rapid tests 
occurred in seven (33.3%) of 21 individuals with AHI. Of those with reactive Determine and 
nonreactive Uni-Gold test results, 35% had AHI. Based on similar findings, Powers et al.[8] 
reported that discordant rapid test results were strongly associated with AHI (unadjusted 
prevalence OR 29.5; 95% CI 8.56–92.48). In developing the UMRSS, Powers and 
colleagues reported that a risk score of ≥ 2 was 95.2% sensitive and 60.5% specific for 
detecting AHI [8]. Accordingly, our study indicated that discordant rapid tests were strongly 
associated with UMRSS > 2, implying a suspicion of early HIV infection in adults with 
these attributes. No participant fulfilled all our study criteria for AHI, and this limitation 
constrains further inferences about the association of discordant rapid tests with detection of 
AHI in this sample. Our inability to identify AHI was not unexpected, as our study 
population generally had a low HIV prevalence. The HIV seroprevalence in our study 
sample was 1%, much lower than the reported prevalence of 3.2% in Nigerian urban 
populations [7]. Typically, AHI is difficult to identify, even among serially tested cohorts of 
high-risk persons. A study among high-risk Nigerians identified 16 cases of AHI in 28 655 
persons screened using the same combination of RDTs that our study utilized [14]. In that 
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cohort, four (0.63%) individuals were identified with AHI of 634 persons who were HIV 
antibody discordant by two RDTs at first testing. An important lesson from our study stems 
from the definition of AHI. We defined AHI as a composite outcome determined by dual-
negative or discordant RDTs at first screening, plus detected plasma HIV-1 RNA > 20 
copies/mL, and negative WB. Three plasma samples closely approached these criteria, but 
had detected plasma HIV-1 RNA < 20 copies/mL, with WB test negative. A result of “< 20 
copies/mL” indicates that HIV-1 RNA was detected, although at a level less than the lower 
quantification limit of the assay used. Due to a lack of approval for follow-up HIV nucleic 
acid tests after the initial encounter, the clinical implications of these subthreshold nucleic 
acid test findings were not determined, but the findings could indicate a false positive result 
(as a consequence of assay variability), or very early HIV-1 infection.
We conclude that, when occurrence of discordance between Determine and Uni-Gold rapid 
assays is < 5% in low HIV prevalence samples, discordant tests in an adult with sexual risk 
behaviour should trigger strong suspicion of early HIV infection.
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Table 1
Results for rapid tests, HIV-1 RNA, and western blot
Serial Number Determine/Uni-Gold RDT result Plasma HIV-1 RNA Western blot n (%) (N = 408)
1. Dual-negative Not detected Not applicable 391 (95.8)
2. Discordant (Determine reactive/Uni-Gold 
nonreactive)
Not detected Not applicable 8 (2.0)
3. Dual-negative Detected (mean VL < 20 
copies/mL)
Negative 3 (0.7)
4. Discordant (Determine nonreactive/Uni-Gold 
reactive)
Not detected Not applicable 2 (0.5)
5. Discordant (Determine reactive/Uni-Gold 
nonreactive)
Detected (mean VL 39 730 
copies/mL)
Positive 2 (0.5)
6. Dual-positive (Determine reactive/Uni-Gold 
reactive)
Detected (mean VL 55 440 
copies/mL)
Positive 2 (0.5)
RDT, rapid diagnostic test; VL, viral load; S/N serial number.
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